HomeCompareHOPHF vs GBDC

HOPHF vs GBDC: Dividend Comparison 2026

HOPHF yields 85.84% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $18.63M in total portfolio value· pulled ahead in Year 8
10 years
HOPHF
HOPHF
● Live price
85.84%
Share price
$2.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.14M
Annual income
$651,617.80
Full HOPHF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — HOPHF vs GBDC

📍 GBDC pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOPHFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOPHF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOPHF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOPHF
Annual income on $10K today (after 15% tax)
$7,296.14/yr
After 10yr DRIP, annual income (after tax)
$553,875.13/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,376,998.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOPHF + GBDC for your $10,000?

HOPHF: 50%GBDC: 50%
100% GBDC50/50100% HOPHF
Portfolio after 10yr
$11.46M
Annual income
$8,520,440.60/yr
Blended yield
74.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

HOPHF
No analyst data
Altman Z
-26.6
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOPHF buys
0
GBDC buys
0
No recent congressional trades found for HOPHF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOPHFGBDC
Forward yield85.84%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$2.14M$20.78M
Annual income after 10y$651,617.80$16,389,263.41
Total dividends collected$1.88M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: HOPHF vs GBDC ($10,000, DRIP)

YearHOPHF PortfolioHOPHF Income/yrGBDC PortfolioGBDC Income/yrGap
1$19,284$8,583.69$12,490$1,790.28+$6.8KHOPHF
2$36,103$15,469.65$16,522$3,157.73+$19.6KHOPHF
3$65,698$27,067.75$23,578$5,898.68+$42.1KHOPHF
4$116,331$46,033.72$37,115$11,886.75+$79.2KHOPHF
5$200,653$76,178.70$66,136$26,423.57+$134.5KHOPHF
6$337,499$122,800.47$137,257$66,491.44+$200.2KHOPHF
7$554,162$193,038.35$341,734$194,868.54+$212.4KHOPHF
8← crossover$889,180$296,226.83$1,050,788$685,133.02$161.6KGBDC
9$1,395,638$444,215.43$4,099,314$2,974,971.01$2.70MGBDC
10$2,144,951$651,617.80$20,775,530$16,389,263.41$18.63MGBDC

HOPHF vs GBDC: Complete Analysis 2026

HOPHFStock

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Full HOPHF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HOPHF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOPHF vs SCHDHOPHF vs JEPIHOPHF vs OHOPHF vs KOHOPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.